| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | granulocyte colony-stimulating factor receptor binding | 2.84e-10 | 14 | 56 | 5 | GO:0005130 | |
| GeneOntologyMolecularFunction | GPI anchor binding | 4.68e-09 | 23 | 56 | 5 | GO:0034235 | |
| GeneOntologyMolecularFunction | filamin binding | 1.63e-08 | 29 | 56 | 5 | GO:0031005 | |
| GeneOntologyMolecularFunction | Toll-like receptor binding | 1.63e-08 | 29 | 56 | 5 | GO:0035325 | |
| GeneOntologyMolecularFunction | bile acid transmembrane transporter activity | 3.78e-08 | 34 | 56 | 5 | GO:0015125 | |
| GeneOntologyMolecularFunction | actin binding | 7.59e-08 | 479 | 56 | 11 | GO:0003779 | |
| GeneOntologyMolecularFunction | glycolipid binding | 2.51e-07 | 49 | 56 | 5 | GO:0051861 | |
| GeneOntologyMolecularFunction | phosphatase binding | 6.89e-07 | 264 | 56 | 8 | GO:0019902 | |
| GeneOntologyMolecularFunction | organic hydroxy compound transmembrane transporter activity | 1.52e-06 | 70 | 56 | 5 | GO:1901618 | |
| GeneOntologyMolecularFunction | lipid transmembrane transporter activity | 1.88e-06 | 73 | 56 | 5 | GO:0170055 | |
| GeneOntologyMolecularFunction | protein phosphatase binding | 1.93e-06 | 210 | 56 | 7 | GO:0019903 | |
| GeneOntologyMolecularFunction | protein tyrosine kinase binding | 3.73e-06 | 149 | 56 | 6 | GO:1990782 | |
| GeneOntologyMolecularFunction | monocarboxylic acid transmembrane transporter activity | 5.30e-06 | 90 | 56 | 5 | GO:0008028 | |
| GeneOntologyMolecularFunction | growth factor receptor binding | 8.79e-06 | 173 | 56 | 6 | GO:0070851 | |
| GeneOntologyMolecularFunction | transmembrane transporter activity | CACNA1F MFSD14B PSG1 TRPM7 PSG3 PSG4 PSG11 TRPV2 SCNN1A LRP5 PSG8 KCNK17 SLC48A1 | 1.75e-05 | 1180 | 56 | 13 | GO:0022857 |
| GeneOntologyMolecularFunction | hexosyltransferase activity | 2.71e-05 | 211 | 56 | 6 | GO:0016758 | |
| GeneOntologyMolecularFunction | transporter activity | CACNA1F MFSD14B PSG1 TRPM7 PSG3 PSG4 PSG11 TRPV2 SCNN1A LRP5 PSG8 KCNK17 SLC48A1 | 4.42e-05 | 1289 | 56 | 13 | GO:0005215 |
| GeneOntologyMolecularFunction | hydrolase activity, acting on glycosyl bonds | 5.17e-05 | 144 | 56 | 5 | GO:0016798 | |
| GeneOntologyMolecularFunction | N,N-dimethylaniline monooxygenase activity | 1.15e-04 | 6 | 56 | 2 | GO:0004499 | |
| GeneOntologyMolecularFunction | glucuronosyltransferase activity | 1.28e-04 | 35 | 56 | 3 | GO:0015020 | |
| GeneOntologyMolecularFunction | glycosyltransferase activity | 1.51e-04 | 288 | 56 | 6 | GO:0016757 | |
| GeneOntologyMolecularFunction | ribosomal protein S6 kinase activity | 1.61e-04 | 7 | 56 | 2 | GO:0004711 | |
| GeneOntologyMolecularFunction | hydrolase activity, hydrolyzing O-glycosyl compounds | 2.00e-04 | 103 | 56 | 4 | GO:0004553 | |
| GeneOntologyMolecularFunction | cytoskeletal protein binding | 2.02e-04 | 1099 | 56 | 11 | GO:0008092 | |
| GeneOntologyMolecularFunction | lipid transporter activity | 2.20e-04 | 196 | 56 | 5 | GO:0005319 | |
| GeneOntologyMolecularFunction | carboxylic acid transmembrane transporter activity | 2.84e-04 | 207 | 56 | 5 | GO:0046943 | |
| GeneOntologyMolecularFunction | organic acid transmembrane transporter activity | 2.90e-04 | 208 | 56 | 5 | GO:0005342 | |
| GeneOntologyMolecularFunction | lysozyme activity | 4.18e-04 | 11 | 56 | 2 | GO:0003796 | |
| GeneOntologyMolecularFunction | calmodulin binding | 4.60e-04 | 230 | 56 | 5 | GO:0005516 | |
| GeneOntologyMolecularFunction | peptidoglycan muralytic activity | 7.92e-04 | 15 | 56 | 2 | GO:0061783 | |
| GeneOntologyMolecularFunction | UDP-glycosyltransferase activity | 8.93e-04 | 153 | 56 | 4 | GO:0008194 | |
| GeneOntologyMolecularFunction | organic anion transmembrane transporter activity | 1.36e-03 | 293 | 56 | 5 | GO:0008514 | |
| GeneOntologyMolecularFunction | phosphatidylinositol binding | 1.90e-03 | 316 | 56 | 5 | GO:0035091 | |
| GeneOntologyMolecularFunction | cytokine receptor binding | 2.12e-03 | 324 | 56 | 5 | GO:0005126 | |
| GeneOntologyMolecularFunction | flavin adenine dinucleotide binding | 2.34e-03 | 94 | 56 | 3 | GO:0050660 | |
| GeneOntologyMolecularFunction | monoatomic cation channel activity | 2.71e-03 | 343 | 56 | 5 | GO:0005261 | |
| GeneOntologyMolecularFunction | retinoic acid binding | 2.79e-03 | 28 | 56 | 2 | GO:0001972 | |
| GeneOntologyMolecularFunction | protein heterodimerization activity | 5.09e-03 | 398 | 56 | 5 | GO:0046982 | |
| GeneOntologyMolecularFunction | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen | 5.63e-03 | 40 | 56 | 2 | GO:0016709 | |
| GeneOntologyMolecularFunction | calcium channel activity | 5.69e-03 | 129 | 56 | 3 | GO:0005262 | |
| GeneOntologyMolecularFunction | lipid binding | 6.01e-03 | 988 | 56 | 8 | GO:0008289 | |
| GeneOntologyMolecularFunction | retinoid binding | 8.02e-03 | 48 | 56 | 2 | GO:0005501 | |
| GeneOntologyMolecularFunction | isoprenoid binding | 8.35e-03 | 49 | 56 | 2 | GO:0019840 | |
| GeneOntologyMolecularFunction | calcium ion transmembrane transporter activity | 8.77e-03 | 151 | 56 | 3 | GO:0015085 | |
| GeneOntologyMolecularFunction | monoatomic ion channel activity | 9.17e-03 | 459 | 56 | 5 | GO:0005216 | |
| GeneOntologyMolecularFunction | metal ion transmembrane transporter activity | 9.66e-03 | 465 | 56 | 5 | GO:0046873 | |
| GeneOntologyMolecularFunction | protein kinase binding | 1.07e-02 | 873 | 56 | 7 | GO:0019901 | |
| GeneOntologyBiologicalProcess | negative regulation of brown fat cell proliferation | 2.00e-10 | 14 | 54 | 5 | GO:0070348 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated immune response to tumor cell | 2.99e-10 | 15 | 54 | 5 | GO:0002856 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated cytotoxicity directed against tumor cell target | 2.99e-10 | 15 | 54 | 5 | GO:0002859 | |
| GeneOntologyBiologicalProcess | regulation of brown fat cell proliferation | 2.99e-10 | 15 | 54 | 5 | GO:0070347 | |
| GeneOntologyBiologicalProcess | positive regulation of homophilic cell adhesion | 2.99e-10 | 15 | 54 | 5 | GO:1903387 | |
| GeneOntologyBiologicalProcess | insulin receptor internalization | 4.35e-10 | 16 | 54 | 5 | GO:0038016 | |
| GeneOntologyBiologicalProcess | brown fat cell proliferation | 6.15e-10 | 17 | 54 | 5 | GO:0070342 | |
| GeneOntologyBiologicalProcess | granulocyte colony-stimulating factor signaling pathway | 6.15e-10 | 17 | 54 | 5 | GO:0038158 | |
| GeneOntologyBiologicalProcess | insulin catabolic process | 6.15e-10 | 17 | 54 | 5 | GO:1901143 | |
| GeneOntologyBiologicalProcess | regulation of homophilic cell adhesion | 8.49e-10 | 18 | 54 | 5 | GO:1903385 | |
| GeneOntologyBiologicalProcess | negative regulation of hepatocyte proliferation | 1.53e-09 | 20 | 54 | 5 | GO:2000346 | |
| GeneOntologyBiologicalProcess | negative regulation of response to tumor cell | 2.01e-09 | 21 | 54 | 5 | GO:0002835 | |
| GeneOntologyBiologicalProcess | negative regulation of immune response to tumor cell | 2.01e-09 | 21 | 54 | 5 | GO:0002838 | |
| GeneOntologyBiologicalProcess | negative regulation of fat cell proliferation | 2.01e-09 | 21 | 54 | 5 | GO:0070345 | |
| GeneOntologyBiologicalProcess | negative regulation of granulocyte differentiation | 2.59e-09 | 22 | 54 | 5 | GO:0030853 | |
| GeneOntologyBiologicalProcess | negative regulation of platelet aggregation | 3.30e-09 | 23 | 54 | 5 | GO:0090331 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated cytotoxicity directed against tumor cell target | 3.30e-09 | 23 | 54 | 5 | GO:0002858 | |
| GeneOntologyBiologicalProcess | positive regulation of vasculogenesis | 4.16e-09 | 24 | 54 | 5 | GO:2001214 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated immune response to tumor cell | 4.16e-09 | 24 | 54 | 5 | GO:0002855 | |
| GeneOntologyBiologicalProcess | natural killer cell mediated cytotoxicity directed against tumor cell target | 4.16e-09 | 24 | 54 | 5 | GO:0002420 | |
| GeneOntologyBiologicalProcess | common myeloid progenitor cell proliferation | 5.19e-09 | 25 | 54 | 5 | GO:0035726 | |
| GeneOntologyBiologicalProcess | natural killer cell mediated immune response to tumor cell | 5.19e-09 | 25 | 54 | 5 | GO:0002423 | |
| GeneOntologyBiologicalProcess | regulation of fat cell proliferation | 7.86e-09 | 27 | 54 | 5 | GO:0070344 | |
| GeneOntologyBiologicalProcess | negative regulation of homotypic cell-cell adhesion | 9.55e-09 | 28 | 54 | 5 | GO:0034111 | |
| GeneOntologyBiologicalProcess | regulation of vasculogenesis | 1.15e-08 | 29 | 54 | 5 | GO:2001212 | |
| GeneOntologyBiologicalProcess | negative regulation of platelet activation | 1.64e-08 | 31 | 54 | 5 | GO:0010544 | |
| GeneOntologyBiologicalProcess | regulation of blood vessel remodeling | 1.94e-08 | 32 | 54 | 5 | GO:0060312 | |
| GeneOntologyBiologicalProcess | negative regulation of bone resorption | 1.94e-08 | 32 | 54 | 5 | GO:0045779 | |
| GeneOntologyBiologicalProcess | fat cell proliferation | 1.94e-08 | 32 | 54 | 5 | GO:0070341 | |
| GeneOntologyBiologicalProcess | negative regulation of feeding behavior | 2.28e-08 | 33 | 54 | 5 | GO:2000252 | |
| GeneOntologyBiologicalProcess | regulation of granulocyte differentiation | 2.28e-08 | 33 | 54 | 5 | GO:0030852 | |
| GeneOntologyBiologicalProcess | negative regulation of vascular permeability | 2.67e-08 | 34 | 54 | 5 | GO:0043116 | |
| GeneOntologyBiologicalProcess | negative regulation of bone remodeling | 2.67e-08 | 34 | 54 | 5 | GO:0046851 | |
| GeneOntologyBiologicalProcess | insulin metabolic process | 3.11e-08 | 35 | 54 | 5 | GO:1901142 | |
| GeneOntologyBiologicalProcess | regulation of fatty acid biosynthetic process | 3.60e-08 | 73 | 54 | 6 | GO:0042304 | |
| GeneOntologyBiologicalProcess | regulation of hepatocyte proliferation | 4.78e-08 | 38 | 54 | 5 | GO:2000345 | |
| GeneOntologyBiologicalProcess | negative regulation of fatty acid biosynthetic process | 5.47e-08 | 39 | 54 | 5 | GO:0045717 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated cytotoxicity | 6.24e-08 | 40 | 54 | 5 | GO:0045953 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated immunity | 7.10e-08 | 41 | 54 | 5 | GO:0002716 | |
| GeneOntologyBiologicalProcess | regulation of platelet aggregation | 8.04e-08 | 42 | 54 | 5 | GO:0090330 | |
| GeneOntologyBiologicalProcess | negative regulation of behavior | 1.15e-07 | 45 | 54 | 5 | GO:0048521 | |
| GeneOntologyBiologicalProcess | epithelial cell proliferation involved in liver morphogenesis | 1.29e-07 | 46 | 54 | 5 | GO:0072575 | |
| GeneOntologyBiologicalProcess | hepatocyte proliferation | 1.29e-07 | 46 | 54 | 5 | GO:0072574 | |
| GeneOntologyBiologicalProcess | bile acid and bile salt transport | 1.44e-07 | 47 | 54 | 5 | GO:0015721 | |
| GeneOntologyBiologicalProcess | negative regulation of leukocyte mediated cytotoxicity | 1.44e-07 | 47 | 54 | 5 | GO:0001911 | |
| GeneOntologyBiologicalProcess | negative regulation of tissue remodeling | 1.44e-07 | 47 | 54 | 5 | GO:0034104 | |
| GeneOntologyBiologicalProcess | liver morphogenesis | 1.78e-07 | 49 | 54 | 5 | GO:0072576 | |
| GeneOntologyBiologicalProcess | regulation of immune response to tumor cell | 1.78e-07 | 49 | 54 | 5 | GO:0002837 | |
| GeneOntologyBiologicalProcess | regulation of response to tumor cell | 1.97e-07 | 50 | 54 | 5 | GO:0002834 | |
| GeneOntologyBiologicalProcess | negative regulation of cell killing | 2.41e-07 | 52 | 54 | 5 | GO:0031342 | |
| GeneOntologyBiologicalProcess | regulation of homotypic cell-cell adhesion | 2.65e-07 | 53 | 54 | 5 | GO:0034110 | |
| GeneOntologyBiologicalProcess | monocarboxylic acid metabolic process | PSG1 PSG3 PSG4 PSG11 UGT2B10 UGT2B15 LPGAT1 UGT2B17 PSG8 ACSF2 GBA2 DEGS1 | 3.14e-07 | 731 | 54 | 12 | GO:0032787 |
| GeneOntologyBiologicalProcess | immune response to tumor cell | 3.51e-07 | 56 | 54 | 5 | GO:0002418 | |
| GeneOntologyBiologicalProcess | import into cell | MRC1 CACNA1F PSG1 PSG3 PSG4 PSG11 RPS6KB1 TRPV2 SCNN1A LRP5 PSG8 VAV3 LY75 SLC48A1 | 4.54e-07 | 1074 | 54 | 14 | GO:0098657 |
| GeneOntologyBiologicalProcess | negative regulation of osteoclast differentiation | 4.58e-07 | 59 | 54 | 5 | GO:0045671 | |
| GeneOntologyBiologicalProcess | granulocyte differentiation | 4.98e-07 | 60 | 54 | 5 | GO:0030851 | |
| GeneOntologyBiologicalProcess | negative regulation of fatty acid metabolic process | 4.98e-07 | 60 | 54 | 5 | GO:0045922 | |
| GeneOntologyBiologicalProcess | regulation of feeding behavior | 5.42e-07 | 61 | 54 | 5 | GO:0060259 | |
| GeneOntologyBiologicalProcess | fatty acid biosynthetic process | 6.41e-07 | 191 | 54 | 7 | GO:0006633 | |
| GeneOntologyBiologicalProcess | regulation of platelet activation | 8.05e-07 | 66 | 54 | 5 | GO:0010543 | |
| GeneOntologyBiologicalProcess | regulation of endothelial cell differentiation | 8.69e-07 | 67 | 54 | 5 | GO:0045601 | |
| GeneOntologyBiologicalProcess | biphenyl catabolic process | 9.41e-07 | 8 | 54 | 3 | GO:0070980 | |
| GeneOntologyBiologicalProcess | bone remodeling | 9.81e-07 | 127 | 54 | 6 | GO:0046849 | |
| GeneOntologyBiologicalProcess | negative regulation of blood coagulation | 1.01e-06 | 69 | 54 | 5 | GO:0030195 | |
| GeneOntologyBiologicalProcess | regulation of bone resorption | 1.08e-06 | 70 | 54 | 5 | GO:0045124 | |
| GeneOntologyBiologicalProcess | negative regulation of hemostasis | 1.08e-06 | 70 | 54 | 5 | GO:1900047 | |
| GeneOntologyBiologicalProcess | regulation of vascular permeability | 1.16e-06 | 71 | 54 | 5 | GO:0043114 | |
| GeneOntologyBiologicalProcess | response to tumor cell | 1.16e-06 | 71 | 54 | 5 | GO:0002347 | |
| GeneOntologyBiologicalProcess | negative regulation of interleukin-1 production | 1.25e-06 | 72 | 54 | 5 | GO:0032692 | |
| GeneOntologyBiologicalProcess | negative regulation of coagulation | 1.25e-06 | 72 | 54 | 5 | GO:0050819 | |
| GeneOntologyBiologicalProcess | regulation of fatty acid metabolic process | 1.34e-06 | 134 | 54 | 6 | GO:0019217 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated cytotoxicity | 1.63e-06 | 76 | 54 | 5 | GO:0042269 | |
| GeneOntologyBiologicalProcess | biphenyl metabolic process | 2.01e-06 | 10 | 54 | 3 | GO:0018879 | |
| GeneOntologyBiologicalProcess | regulation of bone remodeling | 2.11e-06 | 80 | 54 | 5 | GO:0046850 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated immunity | 2.11e-06 | 80 | 54 | 5 | GO:0002715 | |
| GeneOntologyBiologicalProcess | negative regulation of lymphocyte mediated immunity | 2.53e-06 | 83 | 54 | 5 | GO:0002707 | |
| GeneOntologyBiologicalProcess | organic acid metabolic process | FMO3 PSG1 PSG3 PSG4 PSG11 UGT2B10 UGT2B15 LPGAT1 UGT2B17 PSG8 ACSF2 GBA2 DEGS1 | 2.62e-06 | 1064 | 54 | 13 | GO:0006082 |
| GeneOntologyBiologicalProcess | regulation of sprouting angiogenesis | 2.85e-06 | 85 | 54 | 5 | GO:1903670 | |
| GeneOntologyBiologicalProcess | negative regulation of myeloid leukocyte differentiation | 2.85e-06 | 85 | 54 | 5 | GO:0002762 | |
| GeneOntologyBiologicalProcess | regulation of epidermal growth factor receptor signaling pathway | 3.02e-06 | 86 | 54 | 5 | GO:0042058 | |
| GeneOntologyBiologicalProcess | blood vessel remodeling | 3.19e-06 | 87 | 54 | 5 | GO:0001974 | |
| GeneOntologyBiologicalProcess | platelet activation | 3.50e-06 | 158 | 54 | 6 | GO:0030168 | |
| GeneOntologyBiologicalProcess | xenobiotic glucuronidation | 3.67e-06 | 12 | 54 | 3 | GO:0052697 | |
| GeneOntologyBiologicalProcess | negative regulation of lipid biosynthetic process | 3.99e-06 | 91 | 54 | 5 | GO:0051055 | |
| GeneOntologyBiologicalProcess | regulation of blood coagulation | 3.99e-06 | 91 | 54 | 5 | GO:0030193 | |
| GeneOntologyBiologicalProcess | regulation of hemostasis | 4.44e-06 | 93 | 54 | 5 | GO:1900046 | |
| GeneOntologyBiologicalProcess | regulation of ERBB signaling pathway | 4.44e-06 | 93 | 54 | 5 | GO:1901184 | |
| GeneOntologyBiologicalProcess | platelet aggregation | 4.93e-06 | 95 | 54 | 5 | GO:0070527 | |
| GeneOntologyBiologicalProcess | monocarboxylic acid biosynthetic process | 4.98e-06 | 260 | 54 | 7 | GO:0072330 | |
| GeneOntologyBiologicalProcess | negative regulation of leukocyte mediated immunity | 5.19e-06 | 96 | 54 | 5 | GO:0002704 | |
| GeneOntologyBiologicalProcess | regulation of coagulation | 5.19e-06 | 96 | 54 | 5 | GO:0050818 | |
| GeneOntologyBiologicalProcess | negative regulation of wound healing | 5.74e-06 | 98 | 54 | 5 | GO:0061045 | |
| GeneOntologyBiologicalProcess | organic acid biosynthetic process | 5.78e-06 | 377 | 54 | 8 | GO:0016053 | |
| GeneOntologyBiologicalProcess | bone resorption | 6.04e-06 | 99 | 54 | 5 | GO:0045453 | |
| GeneOntologyBiologicalProcess | cellular response to peptide hormone stimulus | 6.24e-06 | 381 | 54 | 8 | GO:0071375 | |
| GeneOntologyBiologicalProcess | phosphatidylinositol 3-kinase/protein kinase B signal transduction | 6.36e-06 | 382 | 54 | 8 | GO:0043491 | |
| GeneOntologyBiologicalProcess | cellular response to insulin stimulus | 6.54e-06 | 271 | 54 | 7 | GO:0032869 | |
| GeneOntologyBiologicalProcess | gland morphogenesis | 6.95e-06 | 178 | 54 | 6 | GO:0022612 | |
| GeneOntologyBiologicalProcess | natural killer cell mediated cytotoxicity | 8.06e-06 | 105 | 54 | 5 | GO:0042267 | |
| GeneOntologyBiologicalProcess | response to peptide hormone | 8.67e-06 | 530 | 54 | 9 | GO:0043434 | |
| GeneOntologyCellularComponent | transforming growth factor beta ligand-receptor complex | 4.91e-10 | 16 | 56 | 5 | GO:0070021 | |
| GeneOntologyCellularComponent | ciliary membrane | 2.44e-07 | 98 | 56 | 6 | GO:0060170 | |
| GeneOntologyCellularComponent | cell surface | MRC1 BTN3A3 PSG1 PSG3 PSG4 PSG7 PSG11 RPS6KB1 TRPV2 SCNN1A RORC PSG8 LY75 GPRC5B | 9.42e-07 | 1111 | 56 | 14 | GO:0009986 |
| GeneOntologyCellularComponent | lateral plasma membrane | 4.25e-06 | 90 | 56 | 5 | GO:0016328 | |
| GeneOntologyCellularComponent | external side of plasma membrane | 8.97e-06 | 519 | 56 | 9 | GO:0009897 | |
| GeneOntologyCellularComponent | serine/threonine protein kinase complex | 6.29e-05 | 157 | 56 | 5 | GO:1902554 | |
| GeneOntologyCellularComponent | T cell receptor complex | 7.51e-05 | 163 | 56 | 5 | GO:0042101 | |
| GeneOntologyCellularComponent | protein kinase complex | 9.16e-05 | 170 | 56 | 5 | GO:1902911 | |
| GeneOntologyCellularComponent | cell projection membrane | 1.46e-04 | 431 | 56 | 7 | GO:0031253 | |
| GeneOntologyCellularComponent | receptor complex | 1.49e-04 | 581 | 56 | 8 | GO:0043235 | |
| GeneOntologyCellularComponent | nuclear outer membrane | 1.68e-04 | 40 | 56 | 3 | GO:0005640 | |
| GeneOntologyCellularComponent | adherens junction | 2.57e-04 | 212 | 56 | 5 | GO:0005912 | |
| GeneOntologyCellularComponent | apical plasma membrane | 3.08e-04 | 487 | 56 | 7 | GO:0016324 | |
| GeneOntologyCellularComponent | plasma membrane signaling receptor complex | 3.39e-04 | 350 | 56 | 6 | GO:0098802 | |
| GeneOntologyCellularComponent | side of membrane | 4.89e-04 | 875 | 56 | 9 | GO:0098552 | |
| GeneOntologyCellularComponent | membrane protein complex | CACNA1F EPS8 EMC7 PSG1 PSG3 PSG4 PSG11 SCNN1A LRP5 PSG8 KCNK17 STT3B | 5.10e-04 | 1498 | 56 | 12 | GO:0098796 |
| GeneOntologyCellularComponent | apical part of cell | 9.82e-04 | 592 | 56 | 7 | GO:0045177 | |
| GeneOntologyCellularComponent | plasma membrane protein complex | 1.10e-03 | 785 | 56 | 8 | GO:0098797 | |
| GeneOntologyCellularComponent | basolateral plasma membrane | 1.64e-03 | 320 | 56 | 5 | GO:0016323 | |
| GeneOntologyCellularComponent | transferase complex, transferring phosphorus-containing groups | 2.01e-03 | 335 | 56 | 5 | GO:0061695 | |
| GeneOntologyCellularComponent | endoplasmic reticulum membrane | EMC7 FMO3 TMX4 UGT2B10 UGT2B15 LPGAT1 UGT2B17 GBA2 DEGS1 STT3B | 2.08e-03 | 1293 | 56 | 10 | GO:0005789 |
| GeneOntologyCellularComponent | endoplasmic reticulum subcompartment | EMC7 FMO3 TMX4 UGT2B10 UGT2B15 LPGAT1 UGT2B17 GBA2 DEGS1 STT3B | 2.15e-03 | 1299 | 56 | 10 | GO:0098827 |
| GeneOntologyCellularComponent | nuclear outer membrane-endoplasmic reticulum membrane network | EMC7 FMO3 TMX4 UGT2B10 UGT2B15 LPGAT1 UGT2B17 GBA2 DEGS1 STT3B | 2.51e-03 | 1327 | 56 | 10 | GO:0042175 |
| GeneOntologyCellularComponent | basal plasma membrane | 2.55e-03 | 354 | 56 | 5 | GO:0009925 | |
| GeneOntologyCellularComponent | basal part of cell | 3.38e-03 | 378 | 56 | 5 | GO:0045178 | |
| GeneOntologyCellularComponent | cell-cell junction | 4.88e-03 | 591 | 56 | 6 | GO:0005911 | |
| GeneOntologyCellularComponent | organelle outer membrane | 6.62e-03 | 279 | 56 | 4 | GO:0031968 | |
| GeneOntologyCellularComponent | outer membrane | 6.79e-03 | 281 | 56 | 4 | GO:0019867 | |
| MousePheno | decreased susceptibility to Coronaviridae infection induced morbidity/mortality | 1.30e-09 | 17 | 43 | 5 | MP:0031047 | |
| MousePheno | increased skeletal muscle triglyceride level | 4.25e-09 | 21 | 43 | 5 | MP:0031415 | |
| MousePheno | decreased fatty acid oxidation | 8.82e-09 | 24 | 43 | 5 | MP:0014172 | |
| MousePheno | increased abdominal fat pad weight | 1.66e-08 | 27 | 43 | 5 | MP:0009286 | |
| MousePheno | decreased susceptibility to Coronaviridae infection | 2.02e-08 | 28 | 43 | 5 | MP:0020950 | |
| MousePheno | abnormal skeletal muscle triglyceride level | 3.47e-08 | 31 | 43 | 5 | MP:0031413 | |
| MousePheno | decreased carbon dioxide production | 3.47e-08 | 31 | 43 | 5 | MP:0008964 | |
| MousePheno | abnormal muscle cell glucose uptake | 5.12e-08 | 67 | 43 | 6 | MP:0004130 | |
| MousePheno | abnormal carbon dioxide production | 5.12e-08 | 67 | 43 | 6 | MP:0008962 | |
| MousePheno | decreased skeletal muscle cell glucose uptake | 6.57e-08 | 35 | 43 | 5 | MP:0031618 | |
| MousePheno | abnormal muscle triglyceride level | 7.61e-08 | 36 | 43 | 5 | MP:0031412 | |
| MousePheno | abnormal vascular wound healing | 8.61e-08 | 73 | 43 | 6 | MP:0004883 | |
| MousePheno | decreased muscle cell glucose uptake | 1.15e-07 | 39 | 43 | 5 | MP:0030022 | |
| MousePheno | decreased susceptibility to Riboviria infection induced morbidity/mortality | 2.15e-07 | 44 | 43 | 5 | MP:0031023 | |
| MousePheno | abnormal skeletal muscle cell glucose uptake | 3.02e-07 | 47 | 43 | 5 | MP:0031617 | |
| MousePheno | abnormal susceptibility to Coronaviridae infection | 3.74e-07 | 49 | 43 | 5 | MP:0020948 | |
| MousePheno | decreased cellular glucose uptake | 5.57e-07 | 53 | 43 | 5 | MP:0003926 | |
| MousePheno | abnormal fatty acid oxidation | 6.13e-07 | 54 | 43 | 5 | MP:0010953 | |
| MousePheno | abnormal cellular glucose uptake | 6.37e-07 | 102 | 43 | 6 | MP:0003925 | |
| MousePheno | abnormal insulin secretion | 8.06e-07 | 171 | 43 | 7 | MP:0003564 | |
| MousePheno | abnormal endocrine pancreas secretion | 9.79e-07 | 176 | 43 | 7 | MP:0014195 | |
| MousePheno | decreased susceptibility to viral infection induced morbidity/mortality | 1.04e-06 | 60 | 43 | 5 | MP:0009790 | |
| MousePheno | abnormal lipid oxidation | 1.13e-06 | 61 | 43 | 5 | MP:0010951 | |
| MousePheno | abnormal pancreas secretion | 1.27e-06 | 183 | 43 | 7 | MP:0002694 | |
| MousePheno | increased insulin secretion | 1.44e-06 | 64 | 43 | 5 | MP:0003058 | |
| MousePheno | decreased susceptibility to infection induced morbidity/mortality | 1.66e-06 | 120 | 43 | 6 | MP:0009786 | |
| MousePheno | abnormal susceptibility to infection induced morbidity/mortality | 1.80e-06 | 279 | 43 | 8 | MP:0009785 | |
| MousePheno | abnormal wound healing | 1.81e-06 | 193 | 43 | 7 | MP:0005023 | |
| MousePheno | abnormal pancreatic beta cell physiology | 2.01e-06 | 196 | 43 | 7 | MP:0003562 | |
| MousePheno | abnormal endocrine pancreas physiology | 2.46e-06 | 202 | 43 | 7 | MP:0010147 | |
| MousePheno | decreased oxygen consumption | 4.13e-06 | 79 | 43 | 5 | MP:0005290 | |
| MousePheno | polyphagia | 4.39e-06 | 80 | 43 | 5 | MP:0001433 | |
| MousePheno | decreased susceptibility to Riboviria infection | 4.96e-06 | 82 | 43 | 5 | MP:0020914 | |
| MousePheno | abnormal colon morphology | 6.55e-06 | 152 | 43 | 6 | MP:0000495 | |
| MousePheno | abnormal induced morbidity/mortality | MRC1 PSG1 TRPM7 PSG3 PSG4 PSG11 TRPV2 RORC PSG8 LY75 SLC48A1 | 9.90e-06 | 737 | 43 | 11 | MP:0001657 |
| MousePheno | abnormal endocrine gland physiology | 1.25e-05 | 363 | 43 | 8 | MP:0013561 | |
| MousePheno | decreased respiratory quotient | 2.09e-05 | 110 | 43 | 5 | MP:0010379 | |
| MousePheno | obese | 2.38e-05 | 113 | 43 | 5 | MP:0001261 | |
| MousePheno | abnormal oxygen consumption | 2.71e-05 | 195 | 43 | 6 | MP:0005288 | |
| MousePheno | abnormal pancreas physiology | 2.73e-05 | 292 | 43 | 7 | MP:0002693 | |
| MousePheno | insulin resistance | 2.87e-05 | 197 | 43 | 6 | MP:0005331 | |
| MousePheno | decreased energy expenditure | 3.05e-05 | 119 | 43 | 5 | MP:0004890 | |
| MousePheno | increased circulating leptin level | 3.87e-05 | 125 | 43 | 5 | MP:0005669 | |
| MousePheno | decreased susceptibility to viral infection | 3.87e-05 | 125 | 43 | 5 | MP:0002410 | |
| MousePheno | increased incidence of tumors by chemical induction | 6.88e-05 | 141 | 43 | 5 | MP:0004499 | |
| MousePheno | abnormal retina blood vessel morphology | 7.49e-05 | 234 | 43 | 6 | MP:0010097 | |
| MousePheno | abnormal glycogen homeostasis | 7.60e-05 | 144 | 43 | 5 | MP:0005438 | |
| MousePheno | abnormal response to injury | 7.75e-05 | 607 | 43 | 9 | MP:0005164 | |
| MousePheno | disorganized retina outer plexiform layer | 9.19e-05 | 5 | 43 | 2 | MP:0008520 | |
| MousePheno | increased hormone level | 1.18e-04 | 641 | 43 | 9 | MP:0014454 | |
| MousePheno | decreased susceptibility to infection | 1.20e-04 | 255 | 43 | 6 | MP:0002409 | |
| MousePheno | abnormal circulating insulin level | 1.30e-04 | 505 | 43 | 8 | MP:0001560 | |
| MousePheno | abnormal abdominal fat pad morphology | 1.39e-04 | 262 | 43 | 6 | MP:0000010 | |
| MousePheno | abnormal blood vessel physiology | 1.80e-04 | 394 | 43 | 7 | MP:0000249 | |
| MousePheno | increased incidence of induced tumors | 1.80e-04 | 173 | 43 | 5 | MP:0002021 | |
| MousePheno | decreased circulating triglyceride level | 1.82e-04 | 275 | 43 | 6 | MP:0002644 | |
| MousePheno | abnormal large intestine morphology | 1.85e-04 | 276 | 43 | 6 | MP:0000489 | |
| MousePheno | abnormal respiratory quotient | 2.06e-04 | 178 | 43 | 5 | MP:0004129 | |
| MousePheno | abnormal vasculature physiology | 2.10e-04 | 404 | 43 | 7 | MP:0031170 | |
| MousePheno | increased circulating insulin level | 2.12e-04 | 283 | 43 | 6 | MP:0002079 | |
| MousePheno | abnormal susceptibility to Riboviria infection | 2.52e-04 | 186 | 43 | 5 | MP:0020912 | |
| MousePheno | increased food intake | 2.72e-04 | 189 | 43 | 5 | MP:0011939 | |
| MousePheno | increased circulating hormone level | 3.28e-04 | 578 | 43 | 8 | MP:0014456 | |
| MousePheno | abnormal fat pad morphology | 3.71e-04 | 314 | 43 | 6 | MP:0005334 | |
| MousePheno | abnormal gas homeostasis | 4.21e-04 | 600 | 43 | 8 | MP:0003948 | |
| MousePheno | abnormal muscle physiology | 5.05e-04 | 954 | 43 | 10 | MP:0002106 | |
| MousePheno | abnormal circulating hormone level | 5.05e-04 | 954 | 43 | 10 | MP:0005418 | |
| MousePheno | impaired glucose tolerance | 5.94e-04 | 480 | 43 | 7 | MP:0005293 | |
| MousePheno | decreased triglyceride level | 6.39e-04 | 348 | 43 | 6 | MP:0005318 | |
| MousePheno | abnormal circulating leptin level | 7.50e-04 | 236 | 43 | 5 | MP:0005667 | |
| MousePheno | abnormal skeletal muscle morphology | 8.31e-04 | 508 | 43 | 7 | MP:0000759 | |
| MousePheno | abnormal susceptibility to infection | 8.90e-04 | 672 | 43 | 8 | MP:0001793 | |
| MousePheno | abnormal gland physiology | 1.07e-03 | 691 | 43 | 8 | MP:0002164 | |
| MousePheno | abnormal consumption behavior | 1.11e-03 | 695 | 43 | 8 | MP:0002069 | |
| MousePheno | abnormal retina vasculature morphology | 1.15e-03 | 390 | 43 | 6 | MP:0002792 | |
| MousePheno | abnormal hormone level | 1.26e-03 | 1073 | 43 | 10 | MP:0003953 | |
| MousePheno | abnormal response to infection | 1.32e-03 | 714 | 43 | 8 | MP:0005025 | |
| MousePheno | abnormal incidence of induced tumors | 1.35e-03 | 269 | 43 | 5 | MP:0013151 | |
| MousePheno | abnormal response to antigen | 1.46e-03 | 726 | 43 | 8 | MP:0020000 | |
| MousePheno | abnormal susceptibility to viral infection | 1.58e-03 | 279 | 43 | 5 | MP:0020185 | |
| MousePheno | abnormal eye vasculature morphology | 1.59e-03 | 415 | 43 | 6 | MP:0031346 | |
| MousePheno | increased physiological sensitivity to xenobiotic | 1.76e-03 | 286 | 43 | 5 | MP:0008873 | |
| MousePheno | abnormal eating behavior | 2.26e-03 | 604 | 43 | 7 | MP:0001431 | |
| MousePheno | abnormal energy expenditure | 2.61e-03 | 313 | 43 | 5 | MP:0005450 | |
| MousePheno | abnormal energy homeostasis | 2.95e-03 | 322 | 43 | 5 | MP:0005448 | |
| MousePheno | thin retina outer plexiform layer | 3.09e-03 | 27 | 43 | 2 | MP:0008519 | |
| Domain | Ig_2 | 6.44e-08 | 73 | 54 | 6 | PF13895 | |
| Domain | V-set | 9.63e-07 | 184 | 54 | 7 | PF07686 | |
| Domain | Ig_V-set | 1.63e-06 | 199 | 54 | 7 | IPR013106 | |
| Domain | FN_type2_col-bd | 8.13e-06 | 14 | 54 | 3 | IPR000562 | |
| Domain | FN2_2 | 8.13e-06 | 14 | 54 | 3 | PS51092 | |
| Domain | fn2 | 8.13e-06 | 14 | 54 | 3 | PF00040 | |
| Domain | FN2_1 | 8.13e-06 | 14 | 54 | 3 | PS00023 | |
| Domain | FN2 | 8.13e-06 | 14 | 54 | 3 | SM00059 | |
| Domain | Ribosomal_S6_kinase | 8.21e-06 | 2 | 54 | 2 | IPR016238 | |
| Domain | LYZL1/LYZL2 | 8.21e-06 | 2 | 54 | 2 | IPR030057 | |
| Domain | ig | 1.76e-05 | 190 | 54 | 6 | PF00047 | |
| Domain | Immunoglobulin | 1.76e-05 | 190 | 54 | 6 | IPR013151 | |
| Domain | UDPGT | 2.93e-05 | 21 | 54 | 3 | PS00375 | |
| Domain | UDPGT | 2.93e-05 | 21 | 54 | 3 | PF00201 | |
| Domain | UDP_glucos_trans | 2.93e-05 | 21 | 54 | 3 | IPR002213 | |
| Domain | NEBU | 4.90e-05 | 4 | 54 | 2 | SM00227 | |
| Domain | NEBULIN | 4.90e-05 | 4 | 54 | 2 | PS51216 | |
| Domain | Nebulin | 4.90e-05 | 4 | 54 | 2 | PF00880 | |
| Domain | Nebulin_repeat | 4.90e-05 | 4 | 54 | 2 | IPR000900 | |
| Domain | Nebulin | 4.90e-05 | 4 | 54 | 2 | IPR013998 | |
| Domain | IGc2 | 5.80e-05 | 235 | 54 | 6 | SM00408 | |
| Domain | Ig_sub2 | 5.80e-05 | 235 | 54 | 6 | IPR003598 | |
| Domain | Kringle-like | 1.07e-04 | 32 | 54 | 3 | IPR013806 | |
| Domain | Glyco_hydro_22_lys | 1.71e-04 | 7 | 54 | 2 | IPR000974 | |
| Domain | Glyco_hydro_22_CS | 1.71e-04 | 7 | 54 | 2 | IPR019799 | |
| Domain | IG | 2.00e-04 | 421 | 54 | 7 | SM00409 | |
| Domain | Ig_sub | 2.00e-04 | 421 | 54 | 7 | IPR003599 | |
| Domain | LACTALBUMIN_LYSOZYME_2 | 2.27e-04 | 8 | 54 | 2 | PS51348 | |
| Domain | Lys | 2.27e-04 | 8 | 54 | 2 | PF00062 | |
| Domain | LACTALBUMIN_LYSOZYME_1 | 2.27e-04 | 8 | 54 | 2 | PS00128 | |
| Domain | LYZ1 | 2.27e-04 | 8 | 54 | 2 | SM00263 | |
| Domain | Glyco_hydro_22 | 2.27e-04 | 8 | 54 | 2 | IPR001916 | |
| Domain | Lysozyme-like_dom | 3.64e-04 | 10 | 54 | 2 | IPR023346 | |
| Domain | IG_LIKE | 5.06e-04 | 491 | 54 | 7 | PS50835 | |
| Domain | Ig-like_dom | 5.84e-04 | 503 | 54 | 7 | IPR007110 | |
| Domain | - | 5.94e-04 | 663 | 54 | 8 | 2.60.40.10 | |
| Domain | - | 6.27e-04 | 13 | 54 | 2 | 2.10.10.10 | |
| Domain | Ig-like_fold | 8.95e-04 | 706 | 54 | 8 | IPR013783 | |
| Domain | RICIN | 2.96e-03 | 28 | 54 | 2 | SM00458 | |
| Domain | RICIN_B_LECTIN | 2.96e-03 | 28 | 54 | 2 | PS50231 | |
| Domain | Ricin_B_lectin | 3.39e-03 | 30 | 54 | 2 | IPR000772 | |
| Domain | Ion_trans_dom | 4.38e-03 | 114 | 54 | 3 | IPR005821 | |
| Domain | Ion_trans | 4.38e-03 | 114 | 54 | 3 | PF00520 | |
| Domain | Pkinase_C | 5.12e-03 | 37 | 54 | 2 | IPR017892 | |
| Domain | Pkinase_C | 6.56e-03 | 42 | 54 | 2 | PF00433 | |
| Domain | C-type_lectin_CS | 6.87e-03 | 43 | 54 | 2 | IPR018378 | |
| Pathway | WP_EGFR1_SIGNALING_PATHWAY | 1.44e-06 | 188 | 43 | 7 | MM15828 | |
| Pathway | REACTOME_CELL_SURFACE_INTERACTIONS_AT_THE_VASCULAR_WALL | 1.78e-06 | 194 | 43 | 7 | M16312 | |
| Pathway | KEGG_PORPHYRIN_AND_CHLOROPHYLL_METABOLISM | 7.00e-06 | 41 | 43 | 4 | M7399 | |
| Pathway | REACTOME_CELL_SURFACE_INTERACTIONS_AT_THE_VASCULAR_WALL | 7.80e-06 | 158 | 43 | 6 | MM14812 | |
| Pathway | REACTOME_POST_TRANSLATIONAL_MODIFICATION_SYNTHESIS_OF_GPI_ANCHORED_PROTEINS | 1.20e-05 | 99 | 43 | 5 | MM14624 | |
| Pathway | REACTOME_PREDNISONE_ADME | 4.49e-05 | 23 | 43 | 3 | MM16639 | |
| Pathway | REACTOME_GLUCURONIDATION | 5.12e-05 | 24 | 43 | 3 | MM14599 | |
| Pathway | REACTOME_GLUCURONIDATION | 5.80e-05 | 25 | 43 | 3 | M17787 | |
| Pathway | WP_GLUCURONIDATION | 5.80e-05 | 25 | 43 | 3 | MM15820 | |
| Pathway | KEGG_ASCORBATE_AND_ALDARATE_METABOLISM | 5.80e-05 | 25 | 43 | 3 | M605 | |
| Pathway | WP_GLUCURONIDATION | 6.55e-05 | 26 | 43 | 3 | M39404 | |
| Pathway | KEGG_DRUG_METABOLISM_CYTOCHROME_P450 | 6.64e-05 | 72 | 43 | 4 | M9257 | |
| Pathway | KEGG_PENTOSE_AND_GLUCURONATE_INTERCONVERSIONS | 8.21e-05 | 28 | 43 | 3 | M19580 | |
| Pathway | REACTOME_EXTRACELLULAR_MATRIX_ORGANIZATION | 1.22e-04 | 258 | 43 | 6 | MM14572 | |
| Pathway | KEGG_MEDICUS_VARIANT_MUTATION_ACTIVATED_PI3K_TO_PI3K_SIGNALING_PATHWAY | 1.89e-04 | 7 | 43 | 2 | M47407 | |
| Pathway | REACTOME_PARACETAMOL_ADME | 2.24e-04 | 39 | 43 | 3 | MM15695 | |
| Pathway | REACTOME_ASPIRIN_ADME | 3.21e-04 | 44 | 43 | 3 | M45014 | |
| Pathway | REACTOME_DRUG_ADME | 3.31e-04 | 109 | 43 | 4 | M45012 | |
| Pathway | REACTOME_ASPIRIN_ADME | 3.43e-04 | 45 | 43 | 3 | MM15694 | |
| Pathway | KEGG_N_GLYCAN_BIOSYNTHESIS | 3.66e-04 | 46 | 43 | 3 | M11079 | |
| Pathway | KEGG_MEDICUS_VARIANT_EGFR_OVEREXPRESSION_TO_PI3K_SIGNALING_PATHWAY | 4.03e-04 | 10 | 43 | 2 | M47400 | |
| Pathway | REACTOME_DRUG_ADME | 4.62e-04 | 119 | 43 | 4 | MM15692 | |
| Pathway | KEGG_MEDICUS_REFERENCE_IGF2_IGF1R_PI3K_SIGNALING_PATHWAY | 4.91e-04 | 11 | 43 | 2 | M47484 | |
| Pathway | KEGG_MEDICUS_REFERENCE_EREG_EGFR_PI3K_SIGNALING_PATHWAY | 4.91e-04 | 11 | 43 | 2 | M47499 | |
| Pathway | KEGG_MEDICUS_REFERENCE_KITLG_KIT_PI3K_SIGNALING_PATHWAY | 4.91e-04 | 11 | 43 | 2 | M47403 | |
| Pathway | KEGG_MEDICUS_REFERENCE_AREG_EGFR_PI3K_SIGNALING_PATHWAY | 4.91e-04 | 11 | 43 | 2 | M47501 | |
| Pathway | KEGG_DRUG_METABOLISM_OTHER_ENZYMES | 4.97e-04 | 51 | 43 | 3 | M17726 | |
| Pathway | KEGG_STARCH_AND_SUCROSE_METABOLISM | 5.26e-04 | 52 | 43 | 3 | M14171 | |
| Pathway | WP_APOPTOSISRELATED_NETWORK_DUE_TO_ALTERED_NOTCH3_IN_OVARIAN_CANCER | 5.57e-04 | 53 | 43 | 3 | M39688 | |
| Pathway | KEGG_MEDICUS_VARIANT_ERBB2_OVEREXPRESSION_TO_PI3K_SIGNALING_PATHWAY | 5.88e-04 | 12 | 43 | 2 | M47393 | |
| Pathway | KEGG_STEROID_HORMONE_BIOSYNTHESIS | 6.21e-04 | 55 | 43 | 3 | M14933 | |
| Pathway | WP_NGLYCAN_BIOSYNTHESIS | 6.90e-04 | 57 | 43 | 3 | M48051 | |
| Pathway | KEGG_MEDICUS_REFERENCE_PDGF_PDGFR_PI3K_SIGNALING_PATHWAY | 6.94e-04 | 13 | 43 | 2 | M47398 | |
| Pathway | REACTOME_HEMOSTASIS | 9.01e-04 | 679 | 43 | 8 | M8395 | |
| Pathway | KEGG_MEDICUS_REFERENCE_RELN_VLDLR_PI3K_SIGNALING_PATHWAY | 9.31e-04 | 15 | 43 | 2 | M47663 | |
| Pathway | KEGG_RETINOL_METABOLISM | 9.68e-04 | 64 | 43 | 3 | M9488 | |
| Pathway | KEGG_METABOLISM_OF_XENOBIOTICS_BY_CYTOCHROME_P450 | 1.26e-03 | 70 | 43 | 3 | M16794 | |
| Pathway | WP_IL18_SIGNALING | 1.38e-03 | 273 | 43 | 5 | M39818 | |
| Pathway | PID_AVB3_INTEGRIN_PATHWAY | 1.47e-03 | 74 | 43 | 3 | M160 | |
| Pathway | REACTOME_HEMOSTASIS | 1.56e-03 | 571 | 43 | 7 | MM14472 | |
| Pathway | WP_TAMOXIFEN_METABOLISM | 1.84e-03 | 21 | 43 | 2 | M39631 | |
| Pathway | WP_METAPATHWAY_BIOTRANSFORMATION_PHASE_I_AND_II | 2.28e-03 | 183 | 43 | 4 | M39588 | |
| Pathway | WP_SPHINGOLIPID_METABOLISM_OVERVIEW | 3.04e-03 | 27 | 43 | 2 | M39863 | |
| Pathway | WP_FOLLICLE_STIMULATING_HORMONE_FSH_SIGNALING | 3.04e-03 | 27 | 43 | 2 | M39609 | |
| Pathway | KEGG_FC_GAMMA_R_MEDIATED_PHAGOCYTOSIS | 3.10e-03 | 96 | 43 | 3 | M16121 | |
| Pathway | REACTOME_TRP_CHANNELS | 3.27e-03 | 28 | 43 | 2 | MM14943 | |
| Pathway | REACTOME_TRP_CHANNELS | 3.27e-03 | 28 | 43 | 2 | M27241 | |
| Pathway | REACTOME_STIMULI_SENSING_CHANNELS | 3.38e-03 | 99 | 43 | 3 | MM14910 | |
| Pathway | KEGG_MEDICUS_REFERENCE_FGF_FGFR_PI3K_SIGNALING_PATHWAY | 4.00e-03 | 31 | 43 | 2 | M47396 | |
| Pathway | REACTOME_STIMULI_SENSING_CHANNELS | 4.10e-03 | 106 | 43 | 3 | M27200 | |
| Pathway | REACTOME_PHASE_II_CONJUGATION_OF_COMPOUNDS | 4.21e-03 | 107 | 43 | 3 | MM14595 | |
| Pathway | REACTOME_NEUTROPHIL_DEGRANULATION | 4.30e-03 | 511 | 43 | 6 | MM15330 | |
| Pathway | REACTOME_BIOLOGICAL_OXIDATIONS | 4.35e-03 | 219 | 43 | 4 | MM14838 | |
| Pathway | REACTOME_BIOLOGICAL_OXIDATIONS | 4.42e-03 | 220 | 43 | 4 | M10320 | |
| Pathway | REACTOME_PHASE_II_CONJUGATION_OF_COMPOUNDS | 4.43e-03 | 109 | 43 | 3 | M18788 | |
| Pubmed | Regulation of hepatic fibrosis by carcinoembryonic antigen-related cell adhesion molecule 1. | 1.26e-11 | 13 | 57 | 5 | 34058224 | |
| Pubmed | A mouse carcinoembryonic antigen gene family member is a calcium-dependent cell adhesion molecule. | 1.26e-11 | 13 | 57 | 5 | 1985902 | |
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 10964771 | ||
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 32169849 | ||
| Pubmed | CEACAM1+ myeloid cells control angiogenesis in inflammation. | 1.26e-11 | 13 | 57 | 5 | 19273835 | |
| Pubmed | Mechanism of glucose intolerance in mice with dominant negative mutation of CEACAM1. | 1.26e-11 | 13 | 57 | 5 | 16638824 | |
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 20044046 | ||
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 32150576 | ||
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 22469976 | ||
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 6265583 | ||
| Pubmed | CEACAM1 creates a pro-angiogenic tumor microenvironment that supports tumor vessel maturation. | 1.26e-11 | 13 | 57 | 5 | 21532628 | |
| Pubmed | Structural and Molecular Evidence Suggesting Coronavirus-driven Evolution of Mouse Receptor. | 1.26e-11 | 13 | 57 | 5 | 28035001 | |
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 34440862 | ||
| Pubmed | CEACAM1 is a potent regulator of B cell receptor complex-induced activation. | 1.26e-11 | 13 | 57 | 5 | 12832451 | |
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 25406283 | ||
| Pubmed | Interaction between altered insulin and lipid metabolism in CEACAM1-inactive transgenic mice. | 1.26e-11 | 13 | 57 | 5 | 15316023 | |
| Pubmed | Crystal structure of mouse coronavirus receptor-binding domain complexed with its murine receptor. | 1.26e-11 | 13 | 57 | 5 | 21670291 | |
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 22162753 | ||
| Pubmed | In vivo adaptation and persistence of Neisseria meningitidis within the nasopharyngeal mucosa. | 1.26e-11 | 13 | 57 | 5 | 23935487 | |
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 2702644 | ||
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 8380065 | ||
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 1279194 | ||
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 15331748 | ||
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 22673933 | ||
| Pubmed | Tumor angiogenesis mediated by myeloid cells is negatively regulated by CEACAM1. | 1.26e-11 | 13 | 57 | 5 | 22406619 | |
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 7628460 | ||
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 25724769 | ||
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 26374765 | ||
| Pubmed | Forced Hepatic Overexpression of CEACAM1 Curtails Diet-Induced Insulin Resistance. | 1.26e-11 | 13 | 57 | 5 | 25972571 | |
| Pubmed | CEACAM1 deficiency delays important wound healing processes. | 1.26e-11 | 13 | 57 | 5 | 22092845 | |
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 11801635 | ||
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 28913658 | ||
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 19008452 | ||
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 18544705 | ||
| Pubmed | Expression of the mouse hepatitis virus receptor by central nervous system microglia. | 1.26e-11 | 13 | 57 | 5 | 15220458 | |
| Pubmed | Expression of the Bgp gene and characterization of mouse colon biliary glycoprotein isoforms. | 1.26e-11 | 13 | 57 | 5 | 8500759 | |
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 18843289 | ||
| Pubmed | Mouse susceptibility to mouse hepatitis virus infection is linked to viral receptor genotype. | 1.26e-11 | 13 | 57 | 5 | 9343248 | |
| Pubmed | Ceacam1 deletion causes vascular alterations in large vessels. | 1.26e-11 | 13 | 57 | 5 | 23800882 | |
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 15207636 | ||
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 19285068 | ||
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 21760897 | ||
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 1719235 | ||
| Pubmed | Mouse hepatitis virus utilizes two carcinoembryonic antigens as alternative receptors. | 1.26e-11 | 13 | 57 | 5 | 1326665 | |
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 21081647 | ||
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 11133662 | ||
| Pubmed | Conditional deletion of CEACAM1 in hepatic stellate cells causes their activation. | 1.26e-11 | 13 | 57 | 5 | 39168268 | |
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 11483763 | ||
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 8402684 | ||
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 2164599 | ||
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 16619040 | ||
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 29377208 | ||
| Pubmed | Expression of MHV-A59 receptor glycoproteins in susceptible and resistant strains of mice. | 1.26e-11 | 13 | 57 | 5 | 8209741 | |
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 27002145 | ||
| Pubmed | Mice with null mutation of Ceacam I develop nonalcoholic steatohepatitis. | 1.26e-11 | 13 | 57 | 5 | 21949477 | |
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 29396368 | ||
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 26219866 | ||
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 18003729 | ||
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 26284027 | ||
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 2133556 | ||
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 32521208 | ||
| Pubmed | CEACAM1 specifically suppresses B cell receptor signaling-mediated activation. | 1.26e-11 | 13 | 57 | 5 | 33352461 | |
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 19406938 | ||
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 38381498 | ||
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 20739537 | ||
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 19621080 | ||
| Pubmed | CEACAM1 promotes CD8+ T cell responses and improves control of a chronic viral infection. | 1.26e-11 | 13 | 57 | 5 | 29967450 | |
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 1633107 | ||
| Pubmed | Expression of newly identified secretory CEACAM1(a) isoforms in the intestinal epithelium. | 1.26e-11 | 13 | 57 | 5 | 19358828 | |
| Pubmed | The role of CEA-related cell adhesion molecule-1 (CEACAM1) in vascular homeostasis. | 1.26e-11 | 13 | 57 | 5 | 27695943 | |
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 20404914 | ||
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 16680193 | ||
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 26911181 | ||
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 1653760 | ||
| Pubmed | Hepatic CEACAM1 expression indicates donor liver quality and prevents early transplantation injury. | 1.26e-11 | 13 | 57 | 5 | 32027621 | |
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 30664851 | ||
| Pubmed | Role for hepatic CEACAM1 in regulating fatty acid metabolism along the adipocyte-hepatocyte axis. | 1.26e-11 | 13 | 57 | 5 | 27777319 | |
| Pubmed | 1.26e-11 | 13 | 57 | 5 | 18848945 | ||
| Pubmed | 1.96e-11 | 14 | 57 | 5 | 37531413 | ||
| Pubmed | 1.96e-11 | 14 | 57 | 5 | 23780386 | ||
| Pubmed | 1.96e-11 | 14 | 57 | 5 | 28567513 | ||
| Pubmed | 1.96e-11 | 14 | 57 | 5 | 8207827 | ||
| Pubmed | Human CEACAM1-LF regulates lipid storage in HepG2 cells via fatty acid transporter CD36. | 1.96e-11 | 14 | 57 | 5 | 34666041 | |
| Pubmed | 1.96e-11 | 14 | 57 | 5 | 19700760 | ||
| Pubmed | 1.96e-11 | 14 | 57 | 5 | 34619794 | ||
| Pubmed | Expression patterns of CD66a and CD117 in the mouse submandibular gland. | 1.96e-11 | 14 | 57 | 5 | 25498293 | |
| Pubmed | Endothelial barrier function is differentially regulated by CEACAM1-mediated signaling. | 1.96e-11 | 14 | 57 | 5 | 29746166 | |
| Pubmed | 1.96e-11 | 14 | 57 | 5 | 9212243 | ||
| Pubmed | CEACAM1 controls the EMT switch in murine mammary carcinoma in vitro and in vivo. | 1.96e-11 | 14 | 57 | 5 | 27572314 | |
| Pubmed | 1.96e-11 | 14 | 57 | 5 | 1648219 | ||
| Pubmed | SHP1 phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule isoforms. | 1.96e-11 | 14 | 57 | 5 | 17081782 | |
| Pubmed | Loss of Ceacam1 promotes prostate cancer progression in Pten haploinsufficient male mice. | 1.96e-11 | 14 | 57 | 5 | 32209360 | |
| Pubmed | 1.96e-11 | 14 | 57 | 5 | 11994468 | ||
| Pubmed | 1.96e-11 | 14 | 57 | 5 | 11850617 | ||
| Pubmed | CEACAM2 positively regulates integrin αIIbβ3-mediated platelet functions. | 1.96e-11 | 14 | 57 | 5 | 27161904 | |
| Pubmed | 1.96e-11 | 14 | 57 | 5 | 20381490 | ||
| Pubmed | CEACAM1 regulates integrin αIIbβ3-mediated functions in platelets. | 1.96e-11 | 14 | 57 | 5 | 26196244 | |
| Pubmed | 1.96e-11 | 14 | 57 | 5 | 8896983 | ||
| Pubmed | 1.96e-11 | 14 | 57 | 5 | 22962327 | ||
| Pubmed | 1.96e-11 | 14 | 57 | 5 | 17623671 | ||
| Interaction | PSG4 interactions | 6.99e-12 | 8 | 55 | 5 | int:PSG4 | |
| Interaction | PSG1 interactions | 1.13e-05 | 51 | 55 | 4 | int:PSG1 | |
| Interaction | PSG3 interactions | 2.86e-05 | 22 | 55 | 3 | int:PSG3 | |
| Cytoband | 19q13.2 | 5.92e-08 | 164 | 57 | 6 | 19q13.2 | |
| Cytoband | 4q13 | 1.57e-04 | 15 | 57 | 2 | 4q13 | |
| Cytoband | 1q24.3 | 2.84e-04 | 20 | 57 | 2 | 1q24.3 | |
| Cytoband | 12q13.11 | 7.33e-04 | 32 | 57 | 2 | 12q13.11 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr4q13 | 1.00e-03 | 157 | 57 | 3 | chr4q13 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr19q13 | 3.55e-03 | 1192 | 57 | 6 | chr19q13 | |
| GeneFamily | CD molecules|V-set domain containing|Pregnancy specific glycoproteins | 3.09e-14 | 11 | 39 | 6 | 1315 | |
| GeneFamily | Adenosine receptors|V-set domain containing | 1.25e-06 | 163 | 39 | 6 | 590 | |
| GeneFamily | UDP glucuronosyltransferases | 4.41e-05 | 32 | 39 | 3 | 363 | |
| GeneFamily | Lysozymes, c-type | 1.62e-04 | 9 | 39 | 2 | 1174 | |
| GeneFamily | C2-set domain containing|Immunoglobulin like domain containing|Scavenger receptors | 1.54e-03 | 27 | 39 | 2 | 1253 | |
| GeneFamily | Transient receptor potential cation channels | 1.65e-03 | 28 | 39 | 2 | 249 | |
| GeneFamily | C-type lectin domain family | 4.61e-03 | 47 | 39 | 2 | 494 | |
| GeneFamily | Endogenous ligands|Minor histocompatibility antigens | 5.41e-03 | 51 | 39 | 2 | 870 | |
| Coexpression | OUYANG_PROSTATE_CANCER_MARKERS | 1.01e-12 | 35 | 57 | 7 | MM757 | |
| Coexpression | BROWN_MYELOID_CELL_DEVELOPMENT_UP | 1.77e-11 | 201 | 57 | 10 | MM1006 | |
| Coexpression | OHGUCHI_LIVER_HNF4A_TARGETS_DN | 5.02e-10 | 201 | 57 | 9 | MM1294 | |
| Coexpression | KOBAYASHI_EGFR_SIGNALING_24HR_UP | 2.47e-09 | 102 | 57 | 7 | M10290 | |
| Coexpression | GIBBONS_GENETIC_MOUSE_MODEL_LUNG_ADENOCARCINOMA_DOWN_IN_METASTASIS | 7.82e-09 | 32 | 57 | 5 | MM2 | |
| Coexpression | MCBRYAN_PUBERTAL_BREAST_3_4WK_UP | 3.55e-08 | 230 | 57 | 8 | MM986 | |
| Coexpression | DESCARTES_FETAL_PLACENTA_TROPHOBLAST_GIANT_CELLS | 5.31e-08 | 93 | 57 | 6 | M40279 | |
| Coexpression | ZHANG_BREAST_CANCER_PROGENITORS_DN | 5.43e-08 | 159 | 57 | 7 | MM760 | |
| Coexpression | WANG_RESPONSE_TO_BEXAROTENE_UP | 6.48e-08 | 48 | 57 | 5 | MM531 | |
| Coexpression | BYSTROEM_CORRELATED_WITH_IL5_DN | 6.25e-07 | 75 | 57 | 5 | MM605 | |
| Coexpression | MCBRYAN_PUBERTAL_BREAST_5_6WK_UP | 6.85e-07 | 143 | 57 | 6 | MM989 | |
| Coexpression | HOFFMAN_CLOCK_TARGETS_UP | 1.16e-06 | 10 | 57 | 3 | M2063 | |
| Coexpression | BOYLAN_MULTIPLE_MYELOMA_PCA3_DN | 1.31e-06 | 87 | 57 | 5 | MM851 | |
| Coexpression | SWEET_LUNG_CANCER_KRAS_UP | 2.13e-06 | 534 | 57 | 9 | MM1050 | |
| Coexpression | MCBRYAN_PUBERTAL_TGFB1_TARGETS_UP | 2.79e-06 | 182 | 57 | 6 | MM993 | |
| Coexpression | TABULA_MURIS_SENIS_SUBCUTANEOUS_ADIPOSE_TISSUE_MYELOID_CELL_AGEING | 8.08e-06 | 219 | 57 | 6 | MM3826 | |
| Coexpression | SCHAEFFER_PROSTATE_DEVELOPMENT_12HR_UP | 8.77e-06 | 128 | 57 | 5 | MM1000 | |
| Coexpression | DESCARTES_FETAL_ADRENAL_CSH1_CSH2_POSITIVE_CELLS | 9.19e-06 | 224 | 57 | 6 | M40145 | |
| Coexpression | HOLLERN_EMT_BREAST_TUMOR_DN | 1.14e-05 | 135 | 57 | 5 | MM965 | |
| Coexpression | CHICAS_RB1_TARGETS_CONFLUENT | 2.97e-05 | 567 | 57 | 8 | M2129 | |
| Coexpression | MCBRYAN_PUBERTAL_BREAST_4_5WK_UP | 3.50e-05 | 284 | 57 | 6 | MM987 | |
| Coexpression | KUMAR_TARGETS_OF_MLL_AF9_FUSION | 6.33e-05 | 463 | 57 | 7 | MM1011 | |
| Coexpression | GSE3982_NKCELL_VS_TH2_UP | 6.95e-05 | 197 | 57 | 5 | M5596 | |
| Coexpression | GSE33292_DN3_THYMOCYTE_VS_TCELL_LYMPHOMA_FROM_TCF1_KO_DN | 7.29e-05 | 199 | 57 | 5 | M9423 | |
| Coexpression | GOTZMANN_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_DN | 8.98e-05 | 208 | 57 | 5 | M1376 | |
| Coexpression | SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP | 9.01e-05 | 490 | 57 | 7 | MM1001 | |
| Coexpression | GOTZMANN_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_DN | 1.22e-04 | 222 | 57 | 5 | MM1132 | |
| Coexpression | THILLAINADESAN_ZNF217_TARGETS_DN | 1.66e-04 | 9 | 57 | 2 | M2199 | |
| Coexpression | HARALAMBIEVA_PBMC_M_M_R_II_AGE_11_22YO_VACCINATED_VS_UNVACCINATED_7YR_DN | 1.89e-04 | 740 | 57 | 8 | M41202 | |
| Coexpression | TABULA_MURIS_SENIS_SUBCUTANEOUS_ADIPOSE_TISSUE_EPITHELIAL_CELL_AGEING | 2.24e-04 | 568 | 57 | 7 | MM3824 | |
| Coexpression | GSE9946_IMMATURE_VS_PROSTAGLANDINE2_TREATED_MATURE_DC_DN | 2.98e-04 | 147 | 57 | 4 | M422 | |
| Coexpression | LIM_MAMMARY_STEM_CELL_DN | 3.63e-04 | 436 | 57 | 6 | MM1326 | |
| ToppCell | TCGA-Cervix-Primary_Tumor-Cervical_Carcinoma-Keratinizing_Cervical_Squamous_Cell_Carcinoma-6|TCGA-Cervix / Sample_Type by Project: Shred V9 | 8.65e-07 | 136 | 57 | 5 | 2c723777fadc5946df67d3e992471d8134b827f4 | |
| ToppCell | kidney_cells-Renal_AKI_(acute_kidney_injury)-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell-Distal_Convoluted_Tubule_Cell_Type_2|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 3.16e-06 | 177 | 57 | 5 | c9e8149639551a4c8daa90fcb2b895fdcff2e2ba | |
| ToppCell | kidney_cells-Hypertensive_with+without-CKD-Epithelial-Collecting_tubule_epithelial_cell-kidney_connecting_tubule_epithelial_cell-Connecting_Tubule_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 5.07e-06 | 195 | 57 | 5 | 3f517c6fc372bdcaf45b3af373414f13cbebd4ba | |
| ToppCell | Bronchial-10x5prime-Immune_Myeloid-Macrophage_alveolar-Macro_alv_dividing|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 5.59e-06 | 199 | 57 | 5 | e1190b1c2d21fed313bb58e24d0e6365de6e6599 | |
| ToppCell | systemic_lupus_erythematosus-managed-Lymphocytic_B-B_plasma-male|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 7.27e-05 | 174 | 57 | 4 | bdbaf805a94b2f5a0065933dab6bf84e3cabd525 | |
| ToppCell | droplet-Marrow-nan-3m-Lymphocytic-NK_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.44e-05 | 175 | 57 | 4 | cf53a15bfb37b6019e7052ffdf594a9ac040900e | |
| ToppCell | 390C-Fibroblasts-Fibroblast-B_(Myofibroblast)|390C / Donor, Lineage, Cell class and subclass (all cells) | 7.60e-05 | 176 | 57 | 4 | 852d3da0907fe87c0ef23d75a63ce07619cf0c54 | |
| ToppCell | 390C-Fibroblasts-Fibroblast-B_(Myofibroblast)-|390C / Donor, Lineage, Cell class and subclass (all cells) | 7.60e-05 | 176 | 57 | 4 | d2df1e435996c51213e88270af9f928e9e09a6f5 | |
| ToppCell | HSPCs-Neutro_prog.|World / Lineage and Cell class | 8.66e-05 | 182 | 57 | 4 | f2512354b90f55bf4172c28084bf52cf79e41d8a | |
| ToppCell | kidney_cells-Hypertensive_with+without-CKD-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell-Distal_Convoluted_Tubule_Cell_Type_2|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 8.84e-05 | 183 | 57 | 4 | 2f0ee40e69ad1259e56e8ee4b352736900eb8901 | |
| ToppCell | TCGA-Thryoid-Primary_Tumor-Thyroid_Papillary_Carcinoma-Classical-4|TCGA-Thryoid / Sample_Type by Project: Shred V9 | 9.03e-05 | 184 | 57 | 4 | d9659d1e4465fec68f48a22edef443f354f6c7cf | |
| ToppCell | 3'-Distal_airway-Immune_Myeloid-Myeloid_macrophage-alveolar_macrophage-Alveolar_macrophage_CCL3+-Alveolar_macrophage_CCL3+_L.1.0.2.2|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 9.61e-05 | 187 | 57 | 4 | 7b24a324335c30c4b37795c43611b297274c804b | |
| ToppCell | droplet-Marrow-nan-3m-Hematologic-megakaryocyte-erythroid_progenitor_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 9.61e-05 | 187 | 57 | 4 | 14c239af77116d28d511dea754b6150d20488080 | |
| ToppCell | droplet-Marrow-BM_(NON-STC)-30m-Lymphocytic-naive_T_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.02e-04 | 190 | 57 | 4 | a1b5775a21d42633224b7d348f0d12b0589dad12 | |
| ToppCell | Fetal_brain-fetalBrain_Zhong_nature-GW19|fetalBrain_Zhong_nature / Sample Type, Dataset, Time_group, and Cell type. | 1.04e-04 | 191 | 57 | 4 | b5328733da3d3d77c4f6fc5e2ba2035f8898f172 | |
| ToppCell | saliva-Mild-Moderate_progression_d12-25-Myeloid-Monocytic-Nonclassical_Monocyte-Mono_c4-CD14-CD16|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.09e-04 | 193 | 57 | 4 | f492ed02a46f3a45dc6005f9f18ab12a84bfa2a3 | |
| ToppCell | 343B-Myeloid-Macrophage-FABP4+_Macrophage_4|343B / Donor, Lineage, Cell class and subclass (all cells) | 1.09e-04 | 193 | 57 | 4 | b9dcffd28ca309359fb110fb79de8ce066208ee1 | |
| ToppCell | normal_Lung|World / Location, Cell class and cell subclass | 1.11e-04 | 194 | 57 | 4 | affae83d7f982d18117f5b95705f09809f304b0b | |
| ToppCell | kidney_cells-Adult_normal_reference-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 1.11e-04 | 194 | 57 | 4 | f08a7618a9ccf12e4a7620235ae662a8abc521af | |
| ToppCell | COPD-Endothelial-Lymphatic|Endothelial / Disease state, Lineage and Cell class | 1.13e-04 | 195 | 57 | 4 | e91ce548ae7224661ee5d2f2639794a5f69798ee | |
| ToppCell | 3'-Distal_airway-Immune_Myeloid-Myeloid_macrophage-alveolar_macrophage-Alveolar_macrophage_CCL3+-Alveolar_macrophage_CCL3+_L.1.0.2.0|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 1.13e-04 | 195 | 57 | 4 | f5351932634d5913688b15f16da76198c91e9b53 | |
| ToppCell | Control-cDC-|Control / Disease condition and Cell class | 1.13e-04 | 195 | 57 | 4 | a2b4d9473eff73f088b247ce43e66f013622471e | |
| ToppCell | 3'-Distal_airway-Immune_Myeloid-Myeloid_macrophage-alveolar_macrophage-Alveolar_macrophage_CCL3+|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 1.13e-04 | 195 | 57 | 4 | c264b052bc50c5bd92816e12fbbe08014d2002f4 | |
| ToppCell | Control-cDC|Control / Disease condition and Cell class | 1.13e-04 | 195 | 57 | 4 | b96acdd22dd3885af69328f170ea871a0d570034 | |
| ToppCell | kidney_cells-Renal_AKI_(acute_kidney_injury)-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 1.15e-04 | 196 | 57 | 4 | f40d10ea7714067585493fdc89744714aa427de8 | |
| ToppCell | (0)_Myeloid-(010)_cDC|(0)_Myeloid / immune cells in Peripheral Blood (logTPM normalization) | 1.15e-04 | 196 | 57 | 4 | ea8cf29a9d4d177d092b0568fd4601cd7f906884 | |
| ToppCell | kidney_cells-Renal_AKI_(acute_kidney_injury)-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell-Degenerative_Distal_Convoluted_Tubule_Cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 1.15e-04 | 196 | 57 | 4 | b8350340d86e4524e9616a427e7f2e116a6fb3be | |
| ToppCell | (3)_MNP-(3)_Macrophage_MARCOpos|(3)_MNP / Lung cell shreds - cell class (v4) and cell subclass (v4) | 1.15e-04 | 196 | 57 | 4 | a4c9f46ff75dbdd43ad369ceda604fb1650d8a9a | |
| ToppCell | 343B-Myeloid-Macrophage|Myeloid / Donor, Lineage, Cell class and subclass (all cells) | 1.17e-04 | 197 | 57 | 4 | 1b6f7a62b7fcfd55c25c5840353eed7183050860 | |
| ToppCell | saliva-Severe-critical_progression_d12-22_no-steroids|saliva / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.17e-04 | 197 | 57 | 4 | c747d05bb032abf8dad46ff6f4d1951bbe64b3b4 | |
| ToppCell | Macrophages-HP_01|World / lung cells shred on cell class, cell subclass, sample id | 1.17e-04 | 197 | 57 | 4 | 598fb7a9a8400af49d90807b3155d3cc1c34f505 | |
| ToppCell | 356C-Myeloid-Macrophage|Myeloid / Donor, Lineage, Cell class and subclass (all cells) | 1.17e-04 | 197 | 57 | 4 | 896242e1651435bbc5b6521417e1aca36c215acd | |
| ToppCell | Healthy-cDC|World / disease group, cell group and cell class | 1.20e-04 | 198 | 57 | 4 | 8976f8d26cb7ff79f74def138c4bbbb0bc2eaf00 | |
| ToppCell | Healthy-cDC|Healthy / disease group, cell group and cell class | 1.20e-04 | 198 | 57 | 4 | 4cf874333b9fd6cd22ee647cd12c032fc6d05740 | |
| ToppCell | 3'-Parenchyma_lung-Immune_Myeloid-Myeloid_macrophage-alveolar_macrophage-Alveolar_macrophage_CCL3+-Alveolar_macrophage_CCL3+_L.1.0.2.0|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 1.20e-04 | 198 | 57 | 4 | 4f167a52fc87bd5e6cfee3a82177d924f417d025 | |
| ToppCell | 3'-Parenchyma_lung-Immune_Myeloid-Myeloid_macrophage-alveolar_macrophage-Alveolar_macrophage_CCL3+|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 1.20e-04 | 198 | 57 | 4 | 6b81e74888f9bd004fcfe51f191c6ce7050cdc36 | |
| ToppCell | distal-3-Hematologic-Alveolar_Macrophage|3 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 1.22e-04 | 199 | 57 | 4 | f57ba6c711e16fe46f8ddc70223576906b3a710b | |
| ToppCell | 10x5'v1-week_14-16-Endothelial-stroma-sinusoidal_EC|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 1.24e-04 | 200 | 57 | 4 | ae429f2de652cc1976e63644781197e9ce0e70c8 | |
| ToppCell | Parenchymal-10x3prime_v2-Stromal-Fibroblastic-Fibro_myofibroblast|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations | 1.24e-04 | 200 | 57 | 4 | 251fd2923f108cd2086961d897244b392c32ad54 | |
| ToppCell | Control-Control-Myeloid-cDC|Control / Disease, condition lineage and cell class | 1.24e-04 | 200 | 57 | 4 | 1375d199320feb85ba06e74b10df6521e790addf | |
| Computational | Neighborhood of CDKN1C | 2.20e-06 | 27 | 38 | 4 | GNF2_CDKN1C | |
| Computational | Neighborhood of EGFR | 4.45e-06 | 32 | 38 | 4 | GNF2_EGFR | |
| Computational | Neighborhood of IGFBP1 | 6.43e-06 | 35 | 38 | 4 | GNF2_IGFBP1 | |
| Computational | Neighborhood of MMP11 | 1.35e-05 | 42 | 38 | 4 | GNF2_MMP11 | |
| Computational | Neighborhood of TIMP2 | 1.95e-05 | 46 | 38 | 4 | GNF2_TIMP2 | |
| Computational | Neighborhood of KISS1 | 2.51e-05 | 49 | 38 | 4 | GNF2_KISS1 | |
| Drug | AC1L1IPV | 1.26e-11 | 43 | 57 | 7 | CID000004683 | |
| Drug | 2-acetylaminofluorene | 1.71e-08 | 262 | 57 | 9 | CID000005897 | |
| Drug | menthol | 8.11e-08 | 87 | 57 | 6 | CID000001254 | |
| Drug | Rgd Peptide | 2.18e-06 | 239 | 57 | 7 | CID000104802 | |
| Drug | 2-AF | 3.34e-06 | 41 | 57 | 4 | CID000005800 | |
| Drug | C1 11-32 | 1.18e-05 | 18 | 57 | 3 | CID000443077 | |
| Drug | C11131 | 1.18e-05 | 18 | 57 | 3 | CID000443076 | |
| Drug | T4-G | 1.40e-05 | 19 | 57 | 3 | CID000152424 | |
| Drug | estriol-16-glucuronide | 1.92e-05 | 21 | 57 | 3 | CID000122281 | |
| Drug | estradiol-3-glucuronide | 2.54e-05 | 23 | 57 | 3 | CID000066651 | |
| Drug | Hymecromone | 3.29e-05 | 25 | 57 | 3 | ctd:D006923 | |
| Drug | eugenol | 3.38e-05 | 73 | 57 | 4 | CID000003314 | |
| Drug | 16-epiestriol | 4.17e-05 | 77 | 57 | 4 | CID000003269 | |
| Drug | L-idaro-1,4-lactone | 4.66e-05 | 28 | 57 | 3 | CID000078997 | |
| Drug | acridine | 5.09e-05 | 81 | 57 | 4 | CID000009215 | |
| Drug | 7-hydroxycoumarin glucuronide | 5.19e-05 | 29 | 57 | 3 | CID000125641 | |
| Drug | 3,5-di-tert-butylquinone | 6.13e-05 | 5 | 57 | 2 | CID000076915 | |
| Drug | SQ20006 | 6.13e-05 | 5 | 57 | 2 | CID000162356 | |
| Drug | 1,6-anhydromuramic acid | 6.13e-05 | 5 | 57 | 2 | CID005492540 | |
| Drug | NNAL | 7.01e-05 | 32 | 57 | 3 | CID000104856 | |
| Drug | Trichostatin A, from Streptomyces sp.; Up 200; 0.1uM; MCF7; HT_HG-U133A | 7.47e-05 | 174 | 57 | 5 | 7179_UP | |
| Drug | AC1Q6OQG | 7.70e-05 | 33 | 57 | 3 | CID000009686 | |
| Drug | BP-3,6-quinol | 7.70e-05 | 33 | 57 | 3 | CID000119292 | |
| Drug | Trichostatin A, from Streptomyces sp.; Up 200; 0.1uM; MCF7; HT_HG-U133A | 8.32e-05 | 178 | 57 | 5 | 6454_UP | |
| Drug | Trichostatin A, Streptomyces sp.; Up 200; 1uM; MCF7; HT_HG-U133A | 8.54e-05 | 179 | 57 | 5 | 6993_UP | |
| Drug | muramic lactam | 9.18e-05 | 6 | 57 | 2 | CID000161874 | |
| Drug | 4-(methylnitrosamino)-1-(3-pyridyl)-1-butan-1-ol | 9.18e-05 | 6 | 57 | 2 | ctd:C475721 | |
| Drug | C-MBT | 9.18e-05 | 6 | 57 | 2 | CID002723842 | |
| Drug | 4-((methylnitrosoamino)-1-(3-pyridyl)but-1-yl)beta-omega-glucosiduronic acid | 9.18e-05 | 6 | 57 | 2 | ctd:C099564 | |
| Drug | 5-mercaptouridine monophosphate | 9.18e-05 | 6 | 57 | 2 | CID003081517 | |
| Drug | lorcaserin | 9.18e-05 | 6 | 57 | 2 | ctd:C506658 | |
| Drug | Arg-Trp | 9.18e-05 | 6 | 57 | 2 | CID006426951 | |
| Drug | AC1NOWCJ | 9.20e-05 | 35 | 57 | 3 | CID005120112 | |
| Drug | 3-[(3S,5R,10S,13R,14S,17R)-3-[(2S,4R,5R,6S)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-14-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one | 9.20e-05 | 35 | 57 | 3 | CID010436171 | |
| Drug | estrone-3-glucuronide | 9.20e-05 | 35 | 57 | 3 | CID000115255 | |
| Drug | l-borneol | 1.09e-04 | 37 | 57 | 3 | CID000010049 | |
| Drug | LY 294002; Down 200; 10uM; MCF7; HT_HG-U133A | 1.16e-04 | 191 | 57 | 5 | 6987_DN | |
| Drug | Endosulfan | 1.22e-04 | 447 | 57 | 7 | ctd:D004726 | |
| Drug | EO-4 | 1.28e-04 | 7 | 57 | 2 | CID006440147 | |
| Drug | Dequalinium dichloride [522-51-0]; Down 200; 7.6uM; MCF7; HT_HG-U133A | 1.31e-04 | 196 | 57 | 5 | 5396_DN | |
| Drug | Kanamycin A sulfate [25389-94-0]; Up 200; 6.8uM; PC3; HT_HG-U133A | 1.34e-04 | 197 | 57 | 5 | 4625_UP | |
| Drug | Trimeprazine tartrate [4330-99-8]; Up 200; 5.4uM; MCF7; HT_HG-U133A | 1.37e-04 | 198 | 57 | 5 | 7235_UP | |
| Drug | harmol | 1.38e-04 | 40 | 57 | 3 | CID000068094 | |
| Drug | gadolinium | 1.40e-04 | 199 | 57 | 5 | CID000023982 | |
| Drug | testosterone glucuronide | 1.48e-04 | 41 | 57 | 3 | CID000108192 | |
| Drug | 2-naphthylamine | 1.67e-04 | 110 | 57 | 4 | CID000007057 | |
| Drug | potassium selenate | 1.71e-04 | 8 | 57 | 2 | CID000062680 | |
| Drug | androsterone glucuronide | 1.71e-04 | 43 | 57 | 3 | CID000114833 | |
| Drug | 7,8-benzoquinoline | 1.71e-04 | 43 | 57 | 3 | CID000009191 | |
| Drug | MS-222 | 1.83e-04 | 44 | 57 | 3 | CID000011400 | |
| Drug | RAWVAWRNR | 2.19e-04 | 9 | 57 | 2 | CID000460901 | |
| Drug | salicylamide | 2.38e-04 | 48 | 57 | 3 | CID000005147 | |
| Drug | H S Q | 2.41e-04 | 351 | 57 | 6 | CID000000897 | |
| Drug | LY303511 | 2.74e-04 | 10 | 57 | 2 | CID000003971 | |
| Disease | cD177 antigen measurement | 3.24e-08 | 18 | 55 | 4 | EFO_0021866 | |
| Disease | deoxycholic acid glucuronide measurement | 3.41e-07 | 8 | 55 | 3 | EFO_0800575 | |
| Disease | X-12007 measurement | 3.41e-06 | 2 | 55 | 2 | EFO_0021276 | |
| Disease | S-methylcysteine measurement | 3.41e-06 | 2 | 55 | 2 | EFO_0800054 | |
| Disease | serum clozapine-to-N-desmethylclozapine ratio measurement | 1.02e-05 | 3 | 55 | 2 | EFO_0600042 | |
| Disease | cholic acid glucuronide measurement | 1.02e-05 | 3 | 55 | 2 | EFO_0800574 | |
| Disease | microphthalmia (is_implicated_in) | 2.04e-05 | 4 | 55 | 2 | DOID:10629 (is_implicated_in) | |
| Disease | X-25937 measurement | 2.04e-05 | 4 | 55 | 2 | EFO_0800937 | |
| Disease | X-16576 measurement | 2.04e-05 | 4 | 55 | 2 | EFO_0800760 | |
| Disease | cotinine measurement, trans-3-hydroxycotinine measurement | 5.09e-05 | 6 | 55 | 2 | EFO_0007813, EFO_0010707 | |
| Disease | cortolone glucuronide (1) measurement | 5.09e-05 | 6 | 55 | 2 | EFO_0800552 | |
| Disease | X-24574 measurement | 7.12e-05 | 7 | 55 | 2 | EFO_0800897 | |
| Disease | vanillylmandelate (VMA) measurement | 7.12e-05 | 7 | 55 | 2 | EFO_0800119 | |
| Disease | serum N-desmethylclozapine measurement | 9.48e-05 | 8 | 55 | 2 | EFO_0600043 | |
| Disease | alcohol dependence (implicated_via_orthology) | 1.22e-04 | 9 | 55 | 2 | DOID:0050741 (implicated_via_orthology) | |
| Disease | plasma clozapine-to-N-desmethylclozapine ratio measurement | 1.22e-04 | 9 | 55 | 2 | EFO_0600040 | |
| Disease | 4-androsten-3alpha,17alpha-diol monosulfate (3) measurement | 1.52e-04 | 10 | 55 | 2 | EFO_0022090 | |
| Disease | bilirubin measurement | 1.70e-04 | 442 | 55 | 6 | EFO_0004570 | |
| Disease | DNA repair protein RAD51 homolog 4 measurement | 1.86e-04 | 11 | 55 | 2 | EFO_0801531 | |
| Disease | plasma N-desmethylclozapine measurement | 1.86e-04 | 11 | 55 | 2 | EFO_0600039 | |
| Disease | 5alpha-androstan-3beta,17beta-diol monosulfate (2) measurement | 2.22e-04 | 12 | 55 | 2 | EFO_0800291 | |
| Disease | androstenediol (3alpha, 17alpha) monosulfate (3) measurement | 2.63e-04 | 13 | 55 | 2 | EFO_0800293 | |
| Disease | X-19141 measurement | 2.63e-04 | 13 | 55 | 2 | EFO_0800799 | |
| Disease | lentiform nucleus measurement | 3.06e-04 | 14 | 55 | 2 | EFO_0004913 | |
| Disease | early cardiac repolarization measurement | 3.06e-04 | 14 | 55 | 2 | EFO_0004885 | |
| Disease | 5alpha-androstan-3alpha,17alpha-diol monosulfate measurement | 3.06e-04 | 14 | 55 | 2 | EFO_0800283 | |
| Disease | non-high density lipoprotein cholesterol measurement | 3.46e-04 | 713 | 55 | 7 | EFO_0005689 | |
| Disease | Hypertensive disease | 4.40e-04 | 190 | 55 | 4 | C0020538 | |
| Disease | 5alpha-androstan-3alpha,17beta-diol monosulfate (1) measurement | 5.12e-04 | 18 | 55 | 2 | EFO_0800288 | |
| Disease | cotinine glucuronidation measurement | 5.72e-04 | 19 | 55 | 2 | EFO_0006508 | |
| Disease | etiocholanolone glucuronide measurement | 5.72e-04 | 19 | 55 | 2 | EFO_0800362 | |
| Disease | androsterone glucuronide measurement | 6.34e-04 | 20 | 55 | 2 | EFO_0800317 | |
| Disease | X-24947 measurement | 7.69e-04 | 22 | 55 | 2 | EFO_0800910 | |
| Disease | obsolete_red blood cell distribution width | 8.00e-04 | 1347 | 55 | 9 | EFO_0005192 | |
| Disease | visual perception measurement | 8.01e-04 | 223 | 55 | 4 | EFO_0009700 | |
| Disease | cotinine measurement | 8.42e-04 | 23 | 55 | 2 | EFO_0007813 | |
| Disease | apolipoprotein A 1 measurement | 9.65e-04 | 848 | 55 | 7 | EFO_0004614 | |
| Disease | epiandrosterone sulfate measurement | 9.96e-04 | 25 | 55 | 2 | EFO_0021120 | |
| Disease | Left Ventricular Hypertrophy | 9.96e-04 | 25 | 55 | 2 | C0149721 | |
| Disease | C-X-C motif chemokine 10 measurement | 1.12e-03 | 109 | 55 | 3 | EFO_0008056 | |
| Disease | urinary metabolite measurement | 1.13e-03 | 245 | 55 | 4 | EFO_0005116 | |
| Disease | glucose metabolism disease (implicated_via_orthology) | 1.25e-03 | 28 | 55 | 2 | DOID:4194 (implicated_via_orthology) | |
| Disease | ferritin measurement | 1.44e-03 | 119 | 55 | 3 | EFO_0004459 | |
| Disease | osteoporosis (is_implicated_in) | 1.53e-03 | 31 | 55 | 2 | DOID:11476 (is_implicated_in) | |
| Disease | docosahexaenoic acid measurement | 1.73e-03 | 127 | 55 | 3 | EFO_0007761 | |
| Disease | androsterone sulfate measurement | 1.74e-03 | 33 | 55 | 2 | EFO_0021117 | |
| Disease | plasma betaine measurement | 1.84e-03 | 34 | 55 | 2 | EFO_0007787 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| GWVKMTPENGYWTMG | 421 | O00478 | |
| RLGMWGPNSYAWVLM | 126 | Q96CM8 | |
| PSEQMFWNAMLKKGW | 121 | P53701 | |
| FWTYMMNARSKNVGW | 266 | P27695 | |
| GWTDVLYWMQDAMGY | 331 | O60840 | |
| GVMRWYQVEGMEWLR | 221 | Q9NRZ9 | |
| YQVEGMEWLRMLWEN | 226 | Q9NRZ9 | |
| MSRVWDNGYPWDMLL | 221 | P31513 | |
| MYKWLLGMVASWGWY | 61 | Q92604 | |
| IVKETQGMNYWQGWK | 116 | Q6UWQ5 | |
| IVKETQGMNYWQGWK | 116 | Q7Z4W2 | |
| YRADVKWMKGMGWVA | 926 | Q86VF7 | |
| KWMKGMGWVATGSLN | 931 | Q86VF7 | |
| QGWQMGVRKVFLKYW | 1121 | Q9Y6X6 | |
| EMSWDKEGKYAMAWG | 451 | P83111 | |
| EGMAVDWMGKNLYWA | 721 | O75197 | |
| WGYWNLNPKQFMTMF | 416 | Q3V5L5 | |
| YKNMVSLWILFGMAW | 241 | Q96T54 | |
| WWSLGALMYDMLTGA | 276 | P23443 | |
| WVMLGITYRNKSLMW | 1311 | O60449 | |
| MSRVWDDGYPWDMMY | 221 | O60774 | |
| MQTMYEQSEWGWKDR | 81 | Q86UY6 | |
| HVMYMQDYWRTWLKG | 56 | Q6P1K1 | |
| IWVAWMTMYLFGNVK | 246 | Q9NZH0 | |
| CKTVQWFRNMMGNAW | 316 | Q6GPH6 | |
| MIKHIGMGLRYLQWW | 111 | Q9HCG7 | |
| VVGETWEKPYQGWMM | 196 | P02751 | |
| AFGNCKAMWNRWFGM | 96 | O15121 | |
| KAMWNRWFGMFANLP | 101 | O15121 | |
| EMMKHAWNNYKGYAW | 201 | P33908 | |
| KRESWGWTDFLMNPM | 151 | Q9NPA0 | |
| DERQLWMSLGGTWMK | 401 | Q12929 | |
| ASYQWWMNGQSLPMT | 176 | Q00888 | |
| ASYLWWMNGQSLPMT | 176 | Q9UQ72 | |
| WLCTFGMMYWQFGLL | 91 | P37088 | |
| AEQRMKKSMWGQFWS | 581 | A3KN83 | |
| LQLAWYGFGSQAWMM | 331 | Q5SR56 | |
| ASYLWWMNGQSLPMT | 176 | P11464 | |
| ASYLWWMNGQSLPMT | 176 | Q16557 | |
| NIMLYKGSGLWSRWK | 126 | P22897 | |
| DWWSLGALMYDMLTG | 251 | Q9UBS0 | |
| ASYLWWMNGQSLPMS | 176 | Q9UQ74 | |
| YLARWGIQGRWMKQD | 131 | Q3SXP7 | |
| ASYLWWMNGQSLPMT | 176 | Q13046 | |
| MGKQLYMHLVWGSWG | 136 | Q8NH09 | |
| KRQEVMKWNGWGYND | 86 | O00116 | |
| KNRTMVQQMWYIWYG | 96 | A4QN01 | |
| NWTLVMEGEWMLKFY | 46 | Q9H1E5 | |
| TGYQRKSMWEMWERC | 306 | P51449 | |
| QQMRLWTQARQMGWY | 371 | Q8WU10 | |
| WTQARQMGWYAAKCM | 376 | Q8WU10 | |
| VMSWWDYGYQIAGMA | 601 | Q8TCJ2 | |
| MENGYWWCRKKQRAG | 671 | Q9Y5S1 | |
| LMDQLGLRLGMWYWK | 21 | Q96LQ0 | |
| LVWAAEYSLWMNMKT | 26 | P36537 | |
| MGKAEMWLIRTYWDF | 251 | P54855 | |
| MWMGRLNMRKNSWYK | 746 | Q96QT4 | |
| MGKAEMWLIRTYWDF | 251 | O75795 | |
| KIYTKMSANGWWRGE | 816 | Q9UKW4 | |
| KRKWMSGNSWANMGQ | 176 | Q8N2G6 | |
| NMYKSDLQWMRGIGW | 2896 | P20929 |